159 related articles for article (PubMed ID: 37672862)
1. Essential cancer medicines: adding feasibility to the magnitude of clinical benefit value chain.
Roitberg F; Amaral T; Cherny NI; Giuliani R; Latino NJ; Galotti M; Bricalli G; Curigliano G; Pentheroudakis G; Trapani D
ESMO Open; 2023 Oct; 8(5):101617. PubMed ID: 37672862
[TBL] [Abstract][Full Text] [Related]
2. Prioritising systemic cancer therapies applying ESMO's tools and other resources to assist in improving cancer care globally: the Kazakh experience.
Latino NJ; Galotti M; Cherny NI; de Vries EGE; Douillard JY; Kaidarova D; Ilbawi A
ESMO Open; 2022 Feb; 7(1):100362. PubMed ID: 35246325
[TBL] [Abstract][Full Text] [Related]
3. Essential medicines for emergency care in Africa.
Broccoli MC; Pigoga JL; Nyirenda M; Wallis L; Calvello Hynes EJ
Emerg Med J; 2018 Jul; 35(7):412-419. PubMed ID: 29627770
[TBL] [Abstract][Full Text] [Related]
4. Overall survival benefits of cancer drugs in the WHO Model List of Essential Medicines, 2015-2021.
Zhou Y; Naci H; Chen D; Bai L; Shi L; Guan X; Wagner AK
BMJ Glob Health; 2023 Sep; 8(9):. PubMed ID: 37775106
[TBL] [Abstract][Full Text] [Related]
5. A multidisciplinary review of the policy, intellectual property rights, and international trade environment for access and affordability to essential cancer medications.
Baxi SM; Beall R; Yang J; Mackey TK
Global Health; 2019 Sep; 15(1):57. PubMed ID: 31533850
[TBL] [Abstract][Full Text] [Related]
6. Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey.
Fundytus A; Sengar M; Lombe D; Hopman W; Jalink M; Gyawali B; Trapani D; Roitberg F; De Vries EGE; Moja L; Ilbawi A; Sullivan R; Booth CM
Lancet Oncol; 2021 Oct; 22(10):1367-1377. PubMed ID: 34560006
[TBL] [Abstract][Full Text] [Related]
7. GRADE Concept 7: Issues and Insights Linking Guideline Recommendations to Trustworthy Essential Medicine Lists.
Piggott T; Moja L; Jenei K; Kredo T; Skoetz N; Banzi R; Trapani D; Leong T; McCaul M; Lavis JN; Akl EA; Nonino F; Iorio A; Laurson-Doube J; Huttner BD; Schünemann HJ
J Clin Epidemiol; 2024 Feb; 166():111241. PubMed ID: 38123105
[TBL] [Abstract][Full Text] [Related]
8. Modernizing the World Health Organization List of Essential Medicines for Preventing and Controlling Cardiovascular Diseases.
Kishore SP; Blank E; Heller DJ; Patel A; Peters A; Price M; Vidula M; Fuster V; Onuma O; Huffman MD; Vedanthan R
J Am Coll Cardiol; 2018 Feb; 71(5):564-574. PubMed ID: 29406862
[TBL] [Abstract][Full Text] [Related]
9. Essential cancer medicines in the national lists of countries of the WHO South-East Asia Region: a descriptive assessment.
Chivukula MV; Tisocki K
WHO South East Asia J Public Health; 2018 Sep; 7(2):90-98. PubMed ID: 30136667
[TBL] [Abstract][Full Text] [Related]
10. Selection of WHO-recommended essential medicines for non-communicable diseases on National Essential Medicines Lists.
Jarvis JD; Woods H; Bali A; Oronsaye E; Persaud N
PLoS One; 2019; 14(8):e0220781. PubMed ID: 31398195
[TBL] [Abstract][Full Text] [Related]
11. Global status of essential medicine selection: a systematic comparison of national essential medicine lists with recommendations by WHO.
Piggott T; Nowak A; Brignardello-Petersen R; Cooke GS; Huttner B; Schünemann HJ; Persaud N; Magrini N; Moja L
BMJ Open; 2022 Feb; 12(2):e053349. PubMed ID: 35144950
[TBL] [Abstract][Full Text] [Related]
12. Access and use of WHO essential medicines in Italy.
Petrella A; Fortinguerra F; Cangini A; Pierantozzi A; Trotta F
Front Public Health; 2023; 11():1211208. PubMed ID: 37881343
[TBL] [Abstract][Full Text] [Related]
13. Analysis of evidence supporting the Federation of Bosnia and Herzegovina reimbursement medicines lists: role of the WHO Essential Medicines List, Cochrane systematic reviews and technology assessment reports.
Mahmić-Kaknjo M; Marušić A
Eur J Clin Pharmacol; 2015 Jul; 71(7):825-33. PubMed ID: 25956715
[TBL] [Abstract][Full Text] [Related]
14. Expanding medicines for neurologic disorders on the WHO Model List.
Rimmer K; Shah H; Thakur K
Neurology; 2017 Mar; 88(10):e87-e91. PubMed ID: 28265046
[TBL] [Abstract][Full Text] [Related]
15. Essential medicines for emergency care in Africa.
Broccoli MC; Pigoga JL; Nyirenda M; Wallis LA; Calvello Hynes EJ
Afr J Emerg Med; 2018 Sep; 8(3):110-117. PubMed ID: 30456159
[TBL] [Abstract][Full Text] [Related]
16. Medicines for cancers in children: The WHO model for selection of essential medicines.
Robertson J; Magrini N; Barr R; Forte G; Ondari C
Pediatr Blood Cancer; 2015 Oct; 62(10):1689-93. PubMed ID: 25929524
[TBL] [Abstract][Full Text] [Related]
17. Quantitative evaluation of essential medicines lists: the South African case study.
Perumal-Pillay VA; Suleman F
BMC Health Serv Res; 2016 Dec; 16(1):687. PubMed ID: 27955710
[TBL] [Abstract][Full Text] [Related]
18. Cancer medicines on the WHO Model List of Essential Medicines: processes, challenges, and a way forward.
Jenei K; Aziz Z; Booth C; Cappello B; Ceppi F; de Vries EGE; Fojo A; Gyawali B; Ilbawi A; Lombe D; Sengar M; Sullivan R; Trapani D; Huttner BD; Moja L
Lancet Glob Health; 2022 Dec; 10(12):e1860-e1866. PubMed ID: 36183737
[TBL] [Abstract][Full Text] [Related]
19. Social networks and health policy: the case of misoprostol and the WHO model essential medicine list.
Millard C; Brhlikova P; Pollock A
Soc Sci Med; 2015 May; 132():190-6. PubMed ID: 25818380
[TBL] [Abstract][Full Text] [Related]
20. Using the WHO essential medicines list to assess the appropriateness of insurance coverage decisions: a case study of the Croatian national medicine reimbursement list.
Jeličić Kadić A; Žanić M; Škaričić N; Marušić A
PLoS One; 2014; 9(10):e111474. PubMed ID: 25337860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
